A Phase 2/3 interventional study of BNT162b2 (Omi XBB.1.5) and BNT162b2 (Omi JN.1) in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 37 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by BioNTech SE · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 12th largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 2/3, and was the 45th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,051 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 15th largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 2/3, and was the 27th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
Substudy A:
This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose,
Substudy B:
This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose,
Substudy C:
This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi JN.1) and BNT162b2 (Omi KP.2) given as a single 30 µg dose to:
SSA
Inclusion Criteria:
Exclusion Criteria
SSB
Inclusion Criteria:
Exclusion Criteria:
SSC
Inclusion Criteria:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants 12 years of age and older, COVID-19 vaccine-experienced will receive 30 µg of BNT162b2 (Omi XBB.1.5) at Visit 1.
Biological: BNT162b2 (Omi XBB.1.5)
Participants 12 years of age and older who were previously exposed to SARS-CoV-2 and are COVID-19 vaccine-naïve will receive 30 μg of BNT162b2 (Omi XBB.1.5) at Visit 1
Biological: BNT162b2 (Omi XBB.1.5)
Cohort 1 - Participants 18 years of age and older will receive 30 µg of BNT162b2 (Omi JN.1) at Visit 1.
Biological: BNT162b2 (Omi JN.1)
Cohort 2 - Participants 12 years of age and older will receive 30 µg of BNT162b2 (Omi JN.1) at Visit 1.
Biological: BNT162b2 (Omi JN.1)
Cohort 3 - Participants 18 years of age and older who will receive 30 µg of BNT162b2 (Omi KP.2) at Visit 1.
Biological: BNT162b2 (Omi KP.2)
BNT162b2 monovalent (Omicron XBB.1.5)
BNT162b2 monovalent (Omicron JN.1)
BNT162b2 monovalent (Omicron KP.2)
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA
Local reactions: pain at injection site, redness and swelling were recorded by participants in an electronic diary (e-diary) or as adverse events (AEs) in the case report form (CRF). Redness and swelling were recorded in measuring device units (mdu) (range: 1 to 21), 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSA
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature more than or equal to (\>=38) degree Celsius (C) and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous (IV) hydration. Diarrhea was graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination: SSA
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A serious AE (SAE) was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From vaccination on Day 1 up to 1 month after vaccination
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSA
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
Time frame: From vaccination on Day 1 up to 6 months after vaccination
Geometric Mean Titers (GMT) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
GMTs and 2-sided 95 percentage (%) confidence interval (CIs) were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ.
Time frame: At 1 month after vaccination
GMT of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: At 1 month after vaccination
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers From Before Study Vaccination to 1 Month After Vaccination: SSA and Historical Control of Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From before vaccination on Day 1 up to 1 month after vaccination
GMFR of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From before vaccination on Day 1 up to 1 month after vaccination
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.
Time frame: At 1 month after vaccination
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.
Time frame: At 1 month after vaccination
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSB
Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSB
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSB
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From vaccination on Day 1 up to 1 month after vaccination
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSB
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
Time frame: From vaccination on Day 1 up to 6 months after vaccination
Geometric Mean Ratio (GMR) of the SARS-CoV-2 XBB.1.5-Neutralizing Titers 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine-Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA
GMTs / GMRs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) means / difference of LS means and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline assay results (log scale), age and vaccine group as covariates. Assay results below the LLOQ were set to 0.5\*LLOQ. GMT was reported in descriptive section and GMR was reported in statistical analysis section
Time frame: At 1 month after vaccination
Percentage of Participants and Difference in Percentage of Participants With Seroresponse to the XBB.1.5 Strain 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA
Seroresponse was defined as achieving \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse. Percentage of participants with seroresponse were reported in descriptive section and difference in percentage of participants with seroresponse in SSB: All Age Groups (Vaccine Naive)- SSA: All Age Groups (Vaccine Experienced Control) were reported in statistical analysis section.
Time frame: At 1 month after vaccination
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From vaccination on Day 1 up to 1 month after vaccination
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
Time frame: From vaccination on Day 1 up to 6 months after vaccination
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 3
Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 3
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 deg C and categorized as \>= 38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and joint pain: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 events were classified by investigator or medically qualified person.
Time frame: Day 1 to Day 7 after vaccination
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 3
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From vaccination on Day 1 up to 1 month after vaccination
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 3
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
Time frame: From vaccination on Day 1 up to 6 months after vaccination
GMTs of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: At 1 month after vaccination
GMFR of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.
Time frame: From before Vaccination to 1 month after Vaccination
Percentage of Participants With Seroresponse to SARS-CoV-2 OMI JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.
Time frame: At 1 month after vaccination
GMTs of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and SSC Cohorts 1 + 2 Combined as Control
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: At 1 month after vaccination
GMFR of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.
Time frame: From before vaccination on Day 1 up to 1 month after vaccination
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.
Time frame: At 1 month after vaccination
In this study there were 3 sub-studies: sub-study A (SSA), sub-study B (SSB), and sub-study C (SSC).
| Milestone | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 30 | 177 | 210 | 9 | 253 | 49 | 18 | 95 | 106 | 51 | 51 |
| Safety population | 30 | 174 | 208 | 9 | 253 | 49 | 18 | 92 | 106 | 51 | 51 |
| Evaluable immunogenicity population | 27 | 167 | 188 | 9 | 243 | 47 | 18 | 91 | 103 | 50 | 50 |
| Completed | 29 | 172 | 203 | 9 | 225 | 44 | 18 | 87 | 100 | 48 | 49 |
| Not completed | 1 | 5 | 7 | 0 | 28 | 5 | 0 | 8 | 6 | 3 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 | 0 | 6 | 1 | 0 | 2 | 1 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 | 22 | 4 | 0 | 3 | 2 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Assigned but not vaccinated | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Local reactions: pain at injection site, redness and swelling were recorded by participants in an electronic diary (e-diary) or as adverse events (AEs) in the case report form (CRF). Redness and swelling were recorded in measuring device units (mdu) (range: 1 to 21), 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
| Percentage of participants | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSA - All Age Groups |
|---|---|---|---|---|
| Redness: Any | 10.0 (2.1 to 26.5) | 4.0 (1.6 to 8.1) | 5.8 (3.0 to 10.0) | 5.4 (3.4 to 8.0) |
| Redness: Mild | 6.7 (0.8 to 22.1) | 3.4 (1.3 to 7.4) | 3.9 (1.7 to 7.5) | 3.9 (2.2 to 6.3) |
| Redness: Moderate | 3.3 (0.1 to 17.2) | 0.6 (0.0 to 3.2) | 1.9 (0.5 to 4.9) | 1.5 (0.5 to 3.2) |
| Redness: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Redness: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Swelling: Any | 16.7 (5.6 to 34.7) | 7.5 (4.0 to 12.4) | 5.8 (3.0 to 10.0) | 7.3 (5.0 to 10.3) |
| Swelling: Mild | 13.3 (3.8 to 30.7) | 5.7 (2.8 to 10.3) | 3.9 (1.7 to 7.5) | 5.4 (3.4 to 8.0) |
| Swelling: Moderate | 3.3 (0.1 to 17.2) | 1.7 (0.4 to 5.0) | 1.9 (0.5 to 4.9) | 2.0 (0.8 to 3.8) |
| Swelling: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Swelling: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Pain at the injection site: Any | 80.0 (61.4 to 92.3) | 75.9 (68.8 to 82.0) | 52.4 (45.4 to 59.4) | 64.4 (59.5 to 69.0) |
| Pain at the injection site: Mild | 50.0 (31.3 to 68.7) | 59.8 (52.1 to 67.1) | 46.6 (39.6 to 53.7) | 52.4 (47.5 to 57.4) |
| Pain at the injection site: Moderate | 30.0 (14.7 to 49.4) | 16.1 (11.0 to 22.4) | 5.8 (3.0 to 10.0) | 12.0 (9.0 to 15.5) |
| Pain at the injection site: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature more than or equal to (\>=38) degree Celsius (C) and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous (IV) hydration. Diarrhea was graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.
| Percentage of participants | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSA - All Age Groups |
|---|---|---|---|---|
| Fever: Any | 16.7 (5.6 to 34.7) | 4.0 (1.6 to 8.1) | 3.9 (1.7 to 7.5) | 4.9 (3.0 to 7.4) |
| Fever: >=38.0 degree C to 38.4 degree C | 10.0 (2.1 to 26.5) | 3.4 (1.3 to 7.4) | 2.4 (0.8 to 5.6) | 3.4 (1.9 to 5.7) |
| Fever: >38.4 degree C to 38.9 degree C | 3.3 (0.1 to 17.2) | 0.6 (0.0 to 3.2) | 1.0 (0.1 to 3.5) | 1.0 (0.3 to 2.5) |
| Fever: >38.9 degree C to 40.0 degree C | 3.3 (0.1 to 17.2) | 0 (0.0 to 2.1) | 0.5 (0.0 to 2.7) | 0.5 (0.1 to 1.8) |
| Fever: >40.0 degree C | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Fatigue: Any | 56.7 (37.4 to 74.5) | 56.9 (49.2 to 64.4) | 35.4 (28.9 to 42.4) | 46.1 (41.2 to 51.1) |
| Fatigue: Mild | 30.0 (14.7 to 49.4) | 31.6 (24.8 to 39.1) | 18.4 (13.4 to 24.4) | 24.9 (20.8 to 29.4) |
| Fatigue: Moderate | 26.7 (12.3 to 45.9) | 24.1 (18.0 to 31.2) | 17.0 (12.1 to 22.8) | 20.7 (16.9 to 25.0) |
| Fatigue: Severe | 0 (0.0 to 11.6) | 1.1 (0.1 to 4.1) | 0 (0.0 to 1.8) | 0.5 (0.1 to 1.8) |
| Fatigue: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Headache: Any | 36.7 (19.9 to 56.1) | 43.7 (36.2 to 51.4) | 26.2 (20.3 to 32.8) | 34.4 (29.8 to 39.2) |
| Headache: Mild | 30.0 (14.7 to 49.4) | 31.0 (24.3 to 38.5) | 20.4 (15.1 to 26.5) | 25.6 (21.5 to 30.1) |
| Headache: Moderate | 6.7 (0.8 to 22.1) | 12.6 (8.1 to 18.5) | 5.8 (3.0 to 10.0) | 8.8 (6.2 to 11.9) |
| Headache: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Headache: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Chills: Any | 20.0 (7.7 to 38.6) | 9.2 (5.3 to 14.5) | 9.2 (5.6 to 14.0) | 10.0 (7.3 to 13.3) |
| Chills: Mild | 10.0 (2.1 to 26.5) | 6.9 (3.6 to 11.7) | 6.3 (3.4 to 10.5) | 6.8 (4.6 to 9.7) |
| Chills: Moderate | 10.0 (2.1 to 26.5) | 2.3 (0.6 to 5.8) | 2.9 (1.1 to 6.2) | 3.2 (1.7 to 5.4) |
| Chills: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Chills: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Vomiting: Any | 0 (0.0 to 11.6) | 2.3 (0.6 to 5.8) | 0 (0.0 to 1.8) | 1.0 (0.3 to 2.5) |
| Vomiting: Mild | 0 (0.0 to 11.6) | 2.3 (0.6 to 5.8) | 0 (0.0 to 1.8) | 1.0 (0.3 to 2.5) |
| Vomiting: Moderate | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Vomiting: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Vomiting: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| Diarrhea: Any | 0 (0.0 to 11.6) | 13.2 (8.6 to 19.2) | 8.7 (5.3 to 13.5) | 10.0 (7.3 to 13.3) |
| Diarrhea: Mild | 0 (0.0 to 11.6) | 11.5 (7.2 to 17.2) | 7.3 (4.1 to 11.7) | 8.5 (6.0 to 11.7) |
| Diarrhea: Moderate | 0 (0.0 to 11.6) | 1.1 (0.1 to 4.1) | 1.5 (0.3 to 4.2) | 1.2 (0.4 to 2.8) |
| Diarrhea: Severe | 0 (0.0 to 11.6) | 0.6 (0.0 to 3.2) | 0 (0.0 to 1.8) | 0.2 (0.0 to 1.4) |
| Diarrhea: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| New or worsened muscle pain: Any | 23.3 (9.9 to 42.3) | 21.8 (15.9 to 28.7) | 12.1 (8.0 to 17.4) | 17.1 (13.6 to 21.1) |
| New or worsened muscle pain: Mild | 3.3 (0.1 to 17.2) | 12.1 (7.6 to 17.9) | 5.3 (2.7 to 9.4) | 8.0 (5.6 to 11.1) |
| New or worsened muscle pain: Moderate | 20.0 (7.7 to 38.6) | 9.8 (5.8 to 15.2) | 6.8 (3.8 to 11.1) | 9.0 (6.4 to 12.2) |
| New or worsened muscle pain: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| New or worsened joint pain: Any | 16.7 (5.6 to 34.7) | 14.4 (9.5 to 20.5) | 7.8 (4.5 to 12.3) | 11.2 (8.3 to 14.7) |
| New or worsened joint pain: Mild | 6.7 (0.8 to 22.1) | 8.6 (4.9 to 13.8) | 5.3 (2.7 to 9.4) | 6.8 (4.6 to 9.7) |
| New or worsened joint pain: Moderate | 10.0 (2.1 to 26.5) | 5.7 (2.8 to 10.3) | 2.4 (0.8 to 5.6) | 4.4 (2.6 to 6.8) |
| New or worsened joint pain: Severe | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 11.6) | 0 (0.0 to 2.1) | 0 (0.0 to 1.8) | 0 (0.0 to 0.9) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A serious AE (SAE) was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSA - All Age Groups |
|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination: SSA | 16.7 (5.6 to 34.7) | 7.5 (4.0 to 12.4) | 8.2 (4.8 to 12.8) | 8.5 (6.0 to 11.6) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
| Percentage of participants | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSA - All Age Groups |
|---|---|---|---|---|
| Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSA | 3.3 (0.1 to 17.2) | 0 (0.0 to 2.1) | 1.9 (0.5 to 4.9) | 1.2 (0.4 to 2.8) |
GMTs and 2-sided 95 percentage (%) confidence interval (CIs) were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ.
| Titer | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | Cohort 2/ 3 From C4591044 - Historical Control: 12-17 Years | Cohort 2/ 3 From C4591044 - Historical Control: 18-55 Years | Cohort 2/ 3 From C4591044 - Historical Control: >55 Years | SSA- All Age Groups | SSA - Historical Control: All Age Groups |
|---|---|---|---|---|---|---|---|---|
| Geometric Mean Titers (GMT) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044 | 3632.1 (2043.8 to 6454.7) | 2503.6 (2003.0 to 3129.3) | 2606.8 (2065.5 to 3289.9) | 837.1 (459.5 to 1524.9) | 615.5 (459.0 to 825.2) | 560.4 (430.0 to 730.2) | 2622.3 (2246.6 to 3060.9) | 601.0 (499.5 to 723.1) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | Cohort 2/ 3 From C4591044 - Historical Control: 12-17 Years | Cohort 2/ 3 From C4591044 - Historical Control: 18-55 Years | Cohort 2/ 3 From C4591044 - Historical Control: >55 Years | SSA- All Age Groups | SSA - Historical Control: All Age Groups |
|---|---|---|---|---|---|---|---|---|
| GMT of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044 | 7903.6 (4961.5 to 12590.4) | 4831.8 (4044.5 to 5772.3) | 5046.1 (4123.3 to 6175.3) | 6376.3 (3568.4 to 11393.8) | 3868.2 (2974.8 to 5029.9) | 4122.7 (3261.2 to 5211.6) | 5105.1 (4483.4 to 5813.0) | 4146.0 (3512.6 to 4893.5) |
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | Cohort 2/ 3 From C4591044 - Historical Control: 12-17 Years | Cohort 2/ 3 From C4591044 - Historical Control: 18-55 Years | Cohort 2/ 3 From C4591044 - Historical Control: >55 Years | SSA- All Age Groups | SSA - Historical Control: All Age Groups |
|---|---|---|---|---|---|---|---|---|
| Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers From Before Study Vaccination to 1 Month After Vaccination: SSA and Historical Control of Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044 | 11.8 (6.3 to 22.2) | 10.7 (8.7 to 13.1) | 13.5 (10.7 to 17.1) | 7.1 (3.9 to 12.8) | 6.1 (4.5 to 8.3) | 5.2 (4.1 to 6.5) | 12.1 (10.4 to 14.0) | 5.7 (4.8 to 6.8) |
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | Cohort 2/ 3 From C4591044 - Historical Control: 12-17 Years | Cohort 2/ 3 From C4591044 - Historical Control: 18-55 Years | Cohort 2/ 3 From C4591044 - Historical Control: >55 Years | SSA- All Age Groups | SSA - Historical Control: All Age Groups |
|---|---|---|---|---|---|---|---|---|
| GMFR of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044 | 3.5 (2.2 to 5.8) | 4.3 (3.7 to 5.0) | 5.1 (4.3 to 6.2) | 5.7 (3.4 to 9.4) | 6.2 (4.6 to 8.4) | 7.4 (5.7 to 9.6) | 4.6 (4.1 to 5.2) | 6.8 (5.6 to 8.1) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.
| Percentage of participants | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | Cohort 2/ 3 From C4591044 - Historical Control: 12-17 Years | Cohort 2/ 3 From C4591044 - Historical Control: 18-55 Years | Cohort 2/ 3 From C4591044 - Historical Control: >55 Years | SSA- All Age Groups | SSA - Historical Control: All Age Groups |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Seroresponse to SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044 | 74.1 (53.7 to 88.9) | 76.4 (69.1 to 82.6) | 71.7 (64.6 to 78.1) | 66.7 (38.4 to 88.2) | 52.4 (41.1 to 63.6) | 51.0 (40.8 to 61.1) | 73.9 (69.2 to 78.3) | 52.8 (45.6 to 59.9) |
Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.
| Percentage of participants | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | Cohort 2/ 3 From C4591044 - Historical Control: 12-17 Years | Cohort 2/ 3 From C4591044 - Historical Control: 18-55 Years | Cohort 2/ 3 From C4591044 - Historical Control: >55 Years | SSA- All Age Groups | SSA - Historical Control: All Age Groups |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Seroresponse to SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044 | 46.2 (26.6 to 66.6) | 43.7 (36.1 to 51.6) | 52.7 (45.3 to 60.0) | 73.3 (44.9 to 92.2) | 58.8 (47.6 to 69.4) | 65.0 (54.8 to 74.3) | 48.3 (43.2 to 53.4) | 63.0 (55.9 to 69.7) |
Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
| Percentage of participants | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSB - All Age Groups |
|---|---|---|---|---|
| Redness: Any | 0 (0.0 to 33.6) | 8.8 (5.6 to 13.0) | 2.0 (0.1 to 10.9) | 7.5 (4.8 to 11.0) |
| Redness: Mild | 0 (0.0 to 33.6) | 5.6 (3.1 to 9.2) | 2.0 (0.1 to 10.9) | 4.9 (2.8 to 7.9) |
| Redness: Moderate | 0 (0.0 to 33.6) | 2.8 (1.1 to 5.7) | 0 (0.0 to 7.3) | 2.3 (0.9 to 4.6) |
| Redness: Severe | 0 (0.0 to 33.6) | 0.4 (0.0 to 2.2) | 0 (0.0 to 7.3) | 0.3 (0.0 to 1.8) |
| Redness: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Swelling: Any | 11.1 (0.3 to 48.2) | 12.0 (8.2 to 16.7) | 10.2 (3.4 to 22.2) | 11.7 (8.3 to 15.8) |
| Swelling: Mild | 11.1 (0.3 to 48.2) | 6.8 (4.0 to 10.7) | 8.2 (2.3 to 19.6) | 7.1 (4.5 to 10.6) |
| Swelling: Moderate | 0 (0.0 to 33.6) | 5.2 (2.8 to 8.7) | 2.0 (0.1 to 10.9) | 4.5 (2.5 to 7.5) |
| Swelling: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Swelling: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Pain at the injection site: Any | 44.4 (13.7 to 78.8) | 58.0 (51.6 to 64.2) | 36.7 (23.4 to 51.7) | 54.2 (48.5 to 59.9) |
| Pain at the injection site: Mild | 44.4 (13.7 to 78.8) | 36.4 (30.4 to 42.7) | 32.7 (19.9 to 47.5) | 36.0 (30.7 to 41.7) |
| Pain at the injection site: Moderate | 0 (0.0 to 33.6) | 21.2 (16.3 to 26.8) | 4.1 (0.5 to 14.0) | 17.9 (13.7 to 22.6) |
| Pain at the injection site: Severe | 0 (0.0 to 33.6) | 0.4 (0.0 to 2.2) | 0 (0.0 to 7.3) | 0.3 (0.0 to 1.8) |
| Pain at the injection site: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.
| Percentage of participants | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSB - All Age Groups |
|---|---|---|---|---|
| Fever: Any | 11.1 (0.3 to 48.2) | 2.4 (0.9 to 5.2) | 6.1 (1.3 to 16.9) | 3.2 (1.6 to 5.9) |
| Fever: >=38.0 degree C to 38.4 degree C | 0 (0.0 to 33.6) | 0.8 (0.1 to 2.9) | 4.1 (0.5 to 14.0) | 1.3 (0.4 to 3.3) |
| Fever: >38.4 degree C to 38.9 degree C | 11.1 (0.3 to 48.2) | 1.2 (0.2 to 3.5) | 0 (0.0 to 7.3) | 1.3 (0.4 to 3.3) |
| Fever: >38.9 degree C to 40.0 degree C | 0 (0.0 to 33.6) | 0.4 (0.0 to 2.2) | 2.0 (0.1 to 10.9) | 0.6 (0.1 to 2.3) |
| Fever: >40.0 degree C | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Fatigue: Any | 11.1 (0.3 to 48.2) | 34.8 (28.9 to 41.1) | 24.5 (13.3 to 38.9) | 32.5 (27.3 to 38.0) |
| Fatigue: Mild | 0 (0.0 to 33.6) | 13.6 (9.6 to 18.5) | 8.2 (2.3 to 19.6) | 12.3 (8.9 to 16.5) |
| Fatigue: Moderate | 11.1 (0.3 to 48.2) | 21.2 (16.3 to 26.8) | 16.3 (7.3 to 29.7) | 20.1 (15.8 to 25.0) |
| Fatigue: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Fatigue: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Headache: Any | 11.1 (0.3 to 48.2) | 30.8 (25.1 to 36.9) | 16.3 (7.3 to 29.7) | 27.9 (23.0 to 33.3) |
| Headache: Mild | 11.1 (0.3 to 48.2) | 12.0 (8.2 to 16.7) | 12.2 (4.6 to 24.8) | 12.0 (8.6 to 16.2) |
| Headache: Moderate | 0 (0.0 to 33.6) | 18.0 (13.4 to 23.3) | 4.1 (0.5 to 14.0) | 15.3 (11.4 to 19.8) |
| Headache: Severe | 0 (0.0 to 33.6) | 0.8 (0.1 to 2.9) | 0 (0.0 to 7.3) | 0.6 (0.1 to 2.3) |
| Headache: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Chills: Any | 11.1 (0.3 to 48.2) | 12.0 (8.2 to 16.7) | 10.2 (3.4 to 22.2) | 11.7 (8.3 to 15.8) |
| Chills: Mild | 11.1 (0.3 to 48.2) | 7.2 (4.3 to 11.1) | 4.1 (0.5 to 14.0) | 6.8 (4.3 to 10.2) |
| Chills: Moderate | 0 (0.0 to 33.6) | 4.8 (2.5 to 8.2) | 6.1 (1.3 to 16.9) | 4.9 (2.8 to 7.9) |
| Chills: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Chills: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Vomiting: Any | 0 (0.0 to 33.6) | 4.8 (2.5 to 8.2) | 2.0 (0.1 to 10.9) | 4.2 (2.3 to 7.1) |
| Vomiting: Mild | 0 (0.0 to 33.6) | 2.4 (0.9 to 5.2) | 2.0 (0.1 to 10.9) | 2.3 (0.9 to 4.6) |
| Vomiting: Moderate | 0 (0.0 to 33.6) | 2.4 (0.9 to 5.2) | 0 (0.0 to 7.3) | 1.9 (0.7 to 4.2) |
| Vomiting: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Vomiting: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| Diarrhea: Any | 11.1 (0.3 to 48.2) | 16.8 (12.4 to 22.0) | 8.2 (2.3 to 19.6) | 15.3 (11.4 to 19.8) |
| Diarrhea: Mild | 11.1 (0.3 to 48.2) | 10.0 (6.6 to 14.4) | 6.1 (1.3 to 16.9) | 9.4 (6.4 to 13.2) |
| Diarrhea: Moderate | 0 (0.0 to 33.6) | 6.4 (3.7 to 10.2) | 2.0 (0.1 to 10.9) | 5.5 (3.2 to 8.7) |
| Diarrhea: Severe | 0 (0.0 to 33.6) | 0.4 (0.0 to 2.2) | 0 (0.0 to 7.3) | 0.3 (0.0 to 1.8) |
| Diarrhea: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| New or worsened muscle pain: Any | 11.1 (0.3 to 48.2) | 18.0 (13.4 to 23.3) | 18.4 (8.8 to 32.0) | 17.9 (13.7 to 22.6) |
| New or worsened muscle pain: Mild | 11.1 (0.3 to 48.2) | 8.0 (5.0 to 12.1) | 10.2 (3.4 to 22.2) | 8.4 (5.6 to 12.1) |
| New or worsened muscle pain: Moderate | 0 (0.0 to 33.6) | 10.0 (6.6 to 14.4) | 8.2 (2.3 to 19.6) | 9.4 (6.4 to 13.2) |
| New or worsened muscle pain: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| New or worsened joint pain: Any | 11.1 (0.3 to 48.2) | 12.8 (8.9 to 17.6) | 12.2 (4.6 to 24.8) | 12.7 (9.2 to 16.9) |
| New or worsened joint pain: Mild | 11.1 (0.3 to 48.2) | 6.4 (3.7 to 10.2) | 6.1 (1.3 to 16.9) | 6.5 (4.0 to 9.9) |
| New or worsened joint pain: Moderate | 0 (0.0 to 33.6) | 6.4 (3.7 to 10.2) | 6.1 (1.3 to 16.9) | 6.2 (3.8 to 9.5) |
| New or worsened joint pain: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 1.5) | 0 (0.0 to 7.3) | 0 (0.0 to 1.2) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSB - All Age Groups |
|---|---|---|---|---|
| Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSB | 0 (0.0 to 33.6) | 2.4 (0.9 to 5.1) | 2.0 (0.1 to 10.9) | 2.3 (0.9 to 4.6) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
| Percentage of participants | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSB - All Age Groups |
|---|---|---|---|---|
| Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSB | 0 (0.0 to 33.6) | 0.8 (0.1 to 2.8) | 2.0 (0.1 to 10.9) | 1.0 (0.2 to 2.8) |
GMTs / GMRs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) means / difference of LS means and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline assay results (log scale), age and vaccine group as covariates. Assay results below the LLOQ were set to 0.5\*LLOQ. GMT was reported in descriptive section and GMR was reported in statistical analysis section
| Titer | SSB: All Age Groups (Vaccine Naive) | SSA: All Age Groups (Vaccine Experienced Control) |
|---|---|---|
| Geometric Mean Ratio (GMR) of the SARS-CoV-2 XBB.1.5-Neutralizing Titers 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine-Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA | 4951.6 (4222.8 to 5806.2) | 2566.5 (2186.8 to 3012.1) |
Seroresponse was defined as achieving \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse. Percentage of participants with seroresponse were reported in descriptive section and difference in percentage of participants with seroresponse in SSB: All Age Groups (Vaccine Naive)- SSA: All Age Groups (Vaccine Experienced Control) were reported in statistical analysis section.
| Percentage of participants | SSB: All Age Groups (Vaccine Naive) | SSA: All Age Groups (Vaccine Experienced Control) |
|---|---|---|
| Percentage of Participants and Difference in Percentage of Participants With Seroresponse to the XBB.1.5 Strain 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA | 84.9 (80.3 to 88.8) | 73.9 (68.5 to 78.8) |
Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
| Percentage of participants | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups |
|---|---|---|---|---|
| Redness: any | 11.1 (1.4 to 34.7) | 8.7 (3.8 to 16.4) | 9.4 (4.6 to 16.7) | 9.3 (5.7 to 13.9) |
| Redness: mild | 5.6 (0.1 to 27.3) | 1.1 (0.0 to 5.9) | 6.6 (2.7 to 13.1) | 4.2 (1.9 to 7.8) |
| Redness: moderate | 5.6 (0.1 to 27.3) | 6.5 (2.4 to 13.7) | 2.8 (0.6 to 8.0) | 4.6 (2.2 to 8.3) |
| Redness: severe | 0 (0.0 to 18.5) | 1.1 (0.0 to 5.9) | 0 (0.0 to 3.4) | 0.5 (0.0 to 2.6) |
| Redness: grade 4 | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0 (0.0 to 1.7) |
| Swelling: any | 0 (0.0 to 18.5) | 13.0 (6.9 to 21.7) | 11.3 (6.0 to 18.9) | 11.1 (7.3 to 16.1) |
| Swelling: mild | 0 (0.0 to 18.5) | 8.7 (3.8 to 16.4) | 4.7 (1.5 to 10.7) | 6.0 (3.2 to 10.1) |
| Swelling: moderate | 0 (0.0 to 18.5) | 4.3 (1.2 to 10.8) | 6.6 (2.7 to 13.1) | 5.1 (2.6 to 8.9) |
| Swelling: severe | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0 (0.0 to 1.7) |
| Swelling: grade 4 | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0 (0.0 to 1.7) |
| Pain at the injection site: any | 88.9 (65.3 to 98.6) | 72.8 (62.6 to 81.6) | 49.1 (39.2 to 59.0) | 62.5 (55.7 to 69.0) |
| Pain at the injection site: mild | 55.6 (30.8 to 78.5) | 58.7 (47.9 to 68.9) | 42.5 (32.9 to 52.4) | 50.5 (43.6 to 57.3) |
| Pain at the injection site: moderate | 27.8 (9.7 to 53.5) | 12.0 (6.1 to 20.4) | 5.7 (2.1 to 11.9) | 10.2 (6.5 to 15.0) |
| Pain at the injection site: severe | 5.6 (0.1 to 27.3) | 2.2 (0.3 to 7.6) | 0.9 (0.0 to 5.1) | 1.9 (0.5 to 4.7) |
| Pain at the injection site: grade 4 | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0 (0.0 to 1.7) |
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.
| Percentage of participants | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups |
|---|---|---|---|---|
| Fever: any | 11.1 (1.4 to 34.7) | 4.3 (1.2 to 10.8) | 1.9 (0.2 to 6.8) | 3.7 (1.6 to 7.2) |
| Fever: >=38.0 degree C to 38.4 degree C | 5.6 (0.1 to 27.3) | 2.2 (0.3 to 7.6) | 1.0 (0.0 to 5.2) | 1.9 (0.5 to 4.7) |
| Fever: >38.4 degree C to 38.9 degree C | 5.6 (0.1 to 27.3) | 2.2 (0.3 to 7.6) | 0 (0.0 to 3.5) | 1.4 (0.3 to 4.0) |
| Fever: >38.9 degree C to 40.0 degree C | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 1.0 (0.0 to 5.2) | 0.5 (0.0 to 2.6) |
| Fever: >40.0 degree C | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.5) | 0 (0.0 to 1.7) |
| Fatigue: any | 55.6 (30.8 to 78.5) | 47.8 (37.3 to 58.5) | 29.2 (20.8 to 38.9) | 39.4 (32.8 to 46.2) |
| Fatigue: mild | 11.1 (1.4 to 34.7) | 22.8 (14.7 to 32.8) | 17.0 (10.4 to 25.5) | 19.0 (14.0 to 24.9) |
| Fatigue: moderate | 38.9 (17.3 to 64.3) | 25.0 (16.6 to 35.1) | 11.3 (6.0 to 18.9) | 19.4 (14.4 to 25.4) |
| Fatigue: severe | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0.9 (0.0 to 5.1) | 0.5 (0.0 to 2.6) |
| Fatigue: grade 4 | 5.6 (0.1 to 27.3) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0.5 (0.0 to 2.6) |
| Headache: any | 61.1 (35.7 to 82.7) | 35.9 (26.1 to 46.5) | 17.9 (11.2 to 26.6) | 29.2 (23.2 to 35.7) |
| Headache: mild | 44.4 (21.5 to 69.2) | 21.7 (13.8 to 31.6) | 13.2 (7.4 to 21.2) | 19.4 (14.4 to 25.4) |
| Headache: moderate | 11.1 (1.4 to 34.7) | 13.0 (6.9 to 21.7) | 3.8 (1.0 to 9.4) | 8.3 (5.0 to 12.9) |
| Headache: severe | 0 (0.0 to 18.5) | 1.1 (0.0 to 5.9) | 0.9 (0.0 to 5.1) | 0.9 (0.1 to 3.3) |
| Headache: grade 4 | 5.6 (0.1 to 27.3) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0.5 (0.0 to 2.6) |
| Chills: any | 44.4 (21.5 to 69.2) | 17.4 (10.3 to 26.7) | 8.5 (4.0 to 15.5) | 15.3 (10.8 to 20.8) |
| Chills: mild | 27.8 (9.7 to 53.5) | 10.9 (5.3 to 19.1) | 4.7 (1.5 to 10.7) | 9.3 (5.7 to 13.9) |
| Chills: moderate | 11.1 (1.4 to 34.7) | 6.5 (2.4 to 13.7) | 2.8 (0.6 to 8.0) | 5.1 (2.6 to 8.9) |
| Chills: severe | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0.9 (0.0 to 5.1) | 0.5 (0.0 to 2.6) |
| Chills: grade 4 | 5.6 (0.1 to 27.3) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0.5 (0.0 to 2.6) |
| Vomiting: any | 11.1 (1.4 to 34.7) | 2.2 (0.3 to 7.6) | 0.9 (0.0 to 5.1) | 2.3 (0.8 to 5.3) |
| Vomiting: mild | 5.6 (0.1 to 27.3) | 2.2 (0.3 to 7.6) | 0 (0.0 to 3.4) | 1.4 (0.3 to 4.0) |
| Vomiting: moderate | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0.9 (0.0 to 5.1) | 0.5 (0.0 to 2.6) |
| Vomiting: severe | 5.6 (0.1 to 27.3) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0.5 (0.0 to 2.6) |
| Vomiting: grade 4 | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0 (0.0 to 1.7) |
| Diarrhoea: any | 0 (0.0 to 18.5) | 9.8 (4.6 to 17.8) | 7.5 (3.3 to 14.3) | 7.9 (4.7 to 12.3) |
| Diarrhoea: mild | 0 (0.0 to 18.5) | 6.5 (2.4 to 13.7) | 6.6 (2.7 to 13.1) | 6.0 (3.2 to 10.1) |
| Diarrhoea: moderate | 0 (0.0 to 18.5) | 3.3 (0.7 to 9.2) | 0.9 (0.0 to 5.1) | 1.9 (0.5 to 4.7) |
| Diarrhoea: severe | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0 (0.0 to 1.7) |
| Diarrhoea: grade 4 | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0 (0.0 to 1.7) |
| New or worsened muscle pain: any | 33.3 (13.3 to 59.0) | 17.4 (10.3 to 26.7) | 10.4 (5.3 to 17.8) | 15.3 (10.8 to 20.8) |
| New or worsened muscle pain: mild | 16.7 (3.6 to 41.4) | 8.7 (3.8 to 16.4) | 5.7 (2.1 to 11.9) | 7.9 (4.7 to 12.3) |
| New or worsened muscle pain: moderate | 11.1 (1.4 to 34.7) | 8.7 (3.8 to 16.4) | 4.7 (1.5 to 10.7) | 6.9 (3.9 to 11.2) |
| New or worsened muscle pain: severe | 5.6 (0.1 to 27.3) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0.5 (0.0 to 2.6) |
| New or worsened muscle pain: grade 4 | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0 (0.0 to 1.7) |
| New or worsened joint pain: any | 11.1 (1.4 to 34.7) | 8.7 (3.8 to 16.4) | 7.5 (3.3 to 14.3) | 8.3 (5.0 to 12.9) |
| New or worsened joint pain: mild | 5.6 (0.1 to 27.3) | 6.5 (2.4 to 13.7) | 3.8 (1.0 to 9.4) | 5.1 (2.6 to 8.9) |
| New or worsened joint pain: moderate | 0 (0.0 to 18.5) | 2.2 (0.3 to 7.6) | 3.8 (1.0 to 9.4) | 2.8 (1.0 to 5.9) |
| New or worsened joint pain: severe | 5.6 (0.1 to 27.3) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0.5 (0.0 to 2.6) |
| New or worsened joint pain: grade 4 | 0 (0.0 to 18.5) | 0 (0.0 to 3.9) | 0 (0.0 to 3.4) | 0 (0.0 to 1.7) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups |
|---|---|---|---|---|
| Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined | 5.6 (0.1 to 27.3) | 3.3 (0.7 to 9.2) | 8.5 (4.0 to 15.5) | 6.0 (3.2 to 10.1) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
| Percentage of participants | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups |
|---|---|---|---|---|
| Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined | 0 (0.0 to 18.5) | 1.1 (0.0 to 5.9) | 2.8 (0.6 to 8.0) | 1.9 (0.5 to 4.7) |
Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.
| Percentage of participants | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | SSC- Cohort 3 Combined: All Age Groups |
|---|---|---|---|
| Redness: any | 5.9 (1.2 to 16.2) | 2.0 (0.0 to 10.4) | 3.9 (1.1 to 9.7) |
| Redness: mild | 2.0 (0.0 to 10.4) | 2.0 (0.0 to 10.4) | 2.0 (0.2 to 6.9) |
| Redness: moderate | 3.9 (0.5 to 13.5) | 0 (0.0 to 7.0) | 2.0 (0.2 to 6.9) |
| Redness: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Redness: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Swelling: any | 9.8 (3.3 to 21.4) | 3.9 (0.5 to 13.5) | 6.9 (2.8 to 13.6) |
| Swelling: mild | 3.9 (0.5 to 13.5) | 3.9 (0.5 to 13.5) | 3.9 (1.1 to 9.7) |
| Swelling: moderate | 5.9 (1.2 to 16.2) | 0 (0.0 to 7.0) | 2.9 (0.6 to 8.4) |
| Swelling: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Swelling: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Pain at the injection site: any | 72.5 (58.3 to 84.1) | 45.1 (31.1 to 59.7) | 58.8 (48.6 to 68.5) |
| Pain at the injection site: mild | 60.8 (46.1 to 74.2) | 39.2 (25.8 to 53.9) | 50.0 (39.9 to 60.1) |
| Pain at the injection site: moderate | 11.8 (4.4 to 23.9) | 5.9 (1.2 to 16.2) | 8.8 (4.1 to 16.1) |
| Pain at the injection site: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Pain at the injection site: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 deg C and categorized as \>= 38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and joint pain: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 events were classified by investigator or medically qualified person.
| Percentage of participants | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | SSC- Cohort 3 Combined: All Age Groups |
|---|---|---|---|
| Fever: any | 3.9 (0.5 to 13.5) | 3.9 (0.5 to 13.5) | 3.9 (1.1 to 9.7) |
| Fever: >=38.0 degree C to 38.4 degree C | 3.9 (0.5 to 13.5) | 2.0 (0.0 to 10.4) | 2.9 (0.6 to 8.4) |
| Fever: >38.4 degree C to 38.9 degree C | 0 (0.0 to 7.0) | 2.0 (0.0 to 10.4) | 1.0 (0.0 to 5.3) |
| Fever: >38.9 degree C to 40.0 degree C | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Fever: >40.0 degree C | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Fatigue: any | 58.8 (44.2 to 72.4) | 33.3 (20.8 to 47.9) | 46.1 (36.2 to 56.2) |
| Fatigue: mild | 33.3 (20.8 to 47.9) | 19.6 (9.8 to 33.1) | 26.5 (18.2 to 36.1) |
| Fatigue: moderate | 25.5 (14.3 to 39.6) | 13.7 (5.7 to 26.3) | 19.6 (12.4 to 28.6) |
| Fatigue: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Fatigue: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Headache: any | 39.2 (25.8 to 53.9) | 17.6 (8.4 to 30.9) | 28.4 (19.9 to 38.2) |
| Headache: mild | 27.5 (15.9 to 41.7) | 11.8 (4.4 to 23.9) | 19.6 (12.4 to 28.6) |
| Headache: moderate | 11.8 (4.4 to 23.9) | 5.9 (1.2 to 16.2) | 8.8 (4.1 to 16.1) |
| Headache: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Headache: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Chills: any | 7.8 (2.2 to 18.9) | 9.8 (3.3 to 21.4) | 8.8 (4.1 to 16.1) |
| Chills: mild | 3.9 (0.5 to 13.5) | 9.8 (3.3 to 21.4) | 6.9 (2.8 to 13.6) |
| Chills: moderate | 3.9 (0.5 to 13.5) | 0 (0.0 to 7.0) | 2.0 (0.2 to 6.9) |
| Chills: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Chills: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Vomiting: any | 2.0 (0.0 to 10.4) | 3.9 (0.5 to 13.5) | 2.9 (0.6 to 8.4) |
| Vomiting: mild | 2.0 (0.0 to 10.4) | 2.0 (0.0 to 10.4) | 2.0 (0.2 to 6.9) |
| Vomiting: moderate | 0 (0.0 to 7.0) | 2.0 (0.0 to 10.4) | 1.0 (0.0 to 5.3) |
| Vomiting: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Vomiting: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Diarrhea: any | 11.8 (4.4 to 23.9) | 7.8 (2.2 to 18.9) | 9.8 (4.8 to 17.3) |
| Diarrhea: mild | 7.8 (2.2 to 18.9) | 7.8 (2.2 to 18.9) | 7.8 (3.4 to 14.9) |
| Diarrhea: moderate | 3.9 (0.5 to 13.5) | 0 (0.0 to 7.0) | 2.0 (0.2 to 6.9) |
| Diarrhea: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| Diarrhea: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| New or worsened muscle pain: any | 33.3 (20.8 to 47.9) | 9.8 (3.3 to 21.4) | 21.6 (14.0 to 30.8) |
| New or worsened muscle pain: mild | 17.6 (8.4 to 30.9) | 7.8 (2.2 to 18.9) | 12.7 (7.0 to 20.8) |
| New or worsened muscle pain: moderate | 15.7 (7.0 to 28.6) | 2.0 (0.0 to 10.4) | 8.8 (4.1 to 16.1) |
| New or worsened muscle pain: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| New or worsened muscle pain: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| New or worsened joint pain: any | 13.7 (5.7 to 26.3) | 3.9 (0.5 to 13.5) | 8.8 (4.1 to 16.1) |
| New or worsened joint pain: mild | 11.8 (4.4 to 23.9) | 2.0 (0.0 to 10.4) | 6.9 (2.8 to 13.6) |
| New or worsened joint pain: moderate | 2.0 (0.0 to 10.4) | 2.0 (0.0 to 10.4) | 2.0 (0.2 to 6.9) |
| New or worsened joint pain: severe | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
| New or worsened joint pain: grade 4 | 0 (0.0 to 7.0) | 0 (0.0 to 7.0) | 0 (0.0 to 3.6) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | SSC- Cohort 3 Combined: All Age Groups |
|---|---|---|---|
| Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 3 | 13.7 (5.7 to 26.3) | 5.9 (1.2 to 16.2) | 9.8 (4.8 to 17.3) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.
| Percentage of participants | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | SSC- Cohort 3 Combined: All Age Groups |
|---|---|---|---|
| Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 3 | 0 (0.0 to 7.0) | 2.0 (0.0 to 10.4) | 1.0 (0.0 to 5.3) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titers | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups | SSA - Historical Control: 12-17 Years | SSA - Historical Control: 18-55 Years | SSA - Historical Control: >55 Years | SSA - Historical Control: All Age Groups |
|---|---|---|---|---|---|---|---|---|
| Omicron JN.1 | 3920.4 (2296.3 to 6693.2) | 1895.8 (1456.8 to 2467.0) | 2275.2 (1771.0 to 2923.1) | 2203.3 (1855.7 to 2616.0) | 1979.1 (928.5 to 4218.1) | 1060.1 (841.8 to 1335.1) | 1090.4 (829.7 to 1433.1) | 1133.8 (950.7 to 1352.2) |
| Omicron XBB.1.5 | 5893.1 (3472.2 to 10002.0) | 1926.7 (1361.8 to 2725.9) | 2415.2 (1815.5 to 3213.1) | 2364.4 (1917.4 to 2915.6) | 5744.9 (3040.8 to 10853.8) | 2566.8 (1963.2 to 3355.9) | 2759.8 (2028.9 to 3753.9) | 2848.1 (2341.9 to 3463.8) |
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.
| Fold rise | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups | SSA - Historical Control: 12-17 Years | SSA - Historical Control: 18-55 Years | SSA - Historical Control: >55 Years | SSA - Historical Control: All Age Groups |
|---|---|---|---|---|---|---|---|---|
| Omicron JN.1 | 15.5 (5.8 to 41.5) | 11.2 (8.3 to 15.0) | 11.4 (8.4 to 15.4) | 11.6 (9.4 to 14.2) | 3.9 (2.5 to 6.1) | 5.8 (4.5 to 7.6) | 9.6 (7.2 to 12.9) | 7.2 (6.0 to 8.7) |
| Omicron XBB.1.5 | 15.9 (6.3 to 40.1) | 7.0 (5.0 to 9.8) | 8.3 (6.0 to 11.4) | 8.1 (6.5 to 10.2) | 10.2 (6.2 to 16.8) | 12.3 (9.4 to 16.1) | 14.2 (11.0 to 18.4) | 13.0 (10.9 to 15.5) |
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.
| Percentage of participants | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups | SSA - Historical Control: 12-17 Years | SSA - Historical Control: 18-55 Years | SSA - Historical Control: >55 Years | SSA - Historical Control: All Age Groups |
|---|---|---|---|---|---|---|---|---|
| Omicron JN.1 | 70.6 (44.0 to 89.7) | 73.6 (63.3 to 82.3) | 68.0 (58.0 to 76.8) | 70.6 (64.0 to 76.7) | 47.1 (23.0 to 72.2) | 63.9 (52.6 to 74.1) | 70.1 (60.0 to 79.0) | 65.5 (58.4 to 72.1) |
| Omicron XBB.1.5 | 66.7 (41.0 to 86.7) | 58.2 (47.4 to 68.5) | 61.2 (51.1 to 70.6) | 60.4 (53.5 to 67.0) | 82.4 (56.6 to 96.2) | 82.4 (72.6 to 89.8) | 81.6 (72.5 to 88.7) | 82.0 (76.0 to 87.1) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Titer | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | SSC- Cohort 3 Combined: All Age Groups | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups |
|---|---|---|---|---|---|---|
| Omicron KP.2 | 2037.8 (1326.3 to 3130.9) | 2498.8 (1590.4 to 3926.0) | 2256.5 (1660.2 to 3067.0) | 890.4 (648.6 to 1222.2) | 858.5 (641.5 to 1148.8) | 873.3 (706.1 to 1080.2) |
| Omicron JN.1 | 3738.8 (2566.9 to 5445.6) | 4990.5 (3309.3 to 7525.7) | 4319.5 (3280.7 to 5687.2) | 1895.8 (1456.8 to 2467.0) | 2275.2 (1771.0 to 2923.1) | 2088.6 (1743.9 to 2501.5) |
GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.
| Fold rise | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | SSC- Cohort 3 Combined: All Age Groups | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups |
|---|---|---|---|---|---|---|
| Omicron KP.2 | 8.9 (6.3 to 12.5) | 13.4 (8.1 to 22.1) | 11.0 (8.1 to 14.8) | 11.4 (8.5 to 15.4) | 10.9 (8.1 to 14.7) | 11.1 (9.0 to 13.7) |
| Omicron JN.1 | 6.6 (4.7 to 9.2) | 11.7 (6.7 to 20.3) | 8.8 (6.4 to 12.1) | 11.2 (8.3 to 15.0) | 11.4 (8.4 to 15.4) | 11.3 (9.1 to 13.9) |
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.
| Percentage of participants | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | SSC- Cohort 3 Combined: All Age Groups | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC- Cohort 1 and Cohort 2 Combined: All Age Groups |
|---|---|---|---|---|---|---|
| Omicron KP.2 | 77.6 (63.4 to 88.2) | 76.0 (61.8 to 86.9) | 76.8 (67.2 to 84.7) | 71.4 (61.0 to 80.4) | 63.1 (53.0 to 72.4) | 67.0 (59.9 to 73.6) |
| Omicron JN.1 | 64.0 (49.2 to 77.1) | 64.0 (49.2 to 77.1) | 64.0 (53.8 to 73.4) | 73.6 (63.3 to 82.3) | 68.0 (58.0 to 76.8) | 70.6 (63.7 to 76.9) |
Collected over Local reactions and systemic events by systematic assessment: Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs and all-cause mortality = from Day 1 of vaccination up to 6 months after vaccination and Non-SAEs = from Day 1 of vaccination up to 1 month after vaccination. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SSA - Group 1: 12-17 Years | 0/30 (0%) | 1/30 (3.3%) | 27/30 (90%) |
| SSA - Group 2: 18-55 Years | 0/174 (0%) | 0/174 (0%) | 154/174 (88.5%) |
| SSA - Group 3: >55 Years | 1/208 (0.5%) | 4/208 (1.9%) | 134/208 (64.4%) |
| SSB - Group 1: 12-17 Years | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| SSB - Group 2: 18-55 Years | 0/253 (0%) | 2/253 (0.8%) | 166/253 (65.6%) |
| SSB - Group 3: >55 Years | 0/49 (0%) | 1/49 (2%) | 25/49 (51%) |
| SSC - Cohort 2: 12-17 Years | 0/18 (0%) | 0/18 (0%) | 16/18 (88.9%) |
| SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | 0/92 (0%) | 1/92 (1.1%) | 77/92 (83.7%) |
| SSC - Cohort 1 and Cohort 2 Combined: >55 Years | 1/106 (0.9%) | 3/106 (2.8%) | 66/106 (62.3%) |
| SSC - Cohort 3: 18-55 Years | 0/51 (0%) | 0/51 (0%) | 43/51 (84.3%) |
| SSC - Cohort 3: >55 Years | 0/51 (0%) | 1/51 (2%) | 35/51 (68.6%) |
| Event | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 1/30 | 0/174 | 0/208 | 0/9 | 0/253 | 0/49 | 0/18 | 0/92 | 0/106 | 0/51 | 0/51 |
| Small intestinal obstructionGastrointestinal disorders | 0/30 | 0/174 | 0/208 | 0/9 | 0/253 | 1/49 | 0/18 | 0/92 | 0/106 | 0/51 | 0/51 |
| Cerebrovascular accidentNervous system disorders | 0/30 | 0/174 | 0/208 | 0/9 | 0/253 | 0/49 | 0/18 | 0/92 | 0/106 | 0/51 | 1/51 |
| DiverticulitisInfections and infestations | 0/30 | 0/174 | 0/208 | 0/9 | 0/253 | 0/49 | 0/18 | 1/92 | 0/106 | 0/51 | 0/51 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 0/30 | 0/174 | 0/208 | 0/9 | 0/253 | 0/49 | 0/18 | 0/92 | 1/106 | 0/51 | 0/51 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/30 | 0/174 | 0/208 | 0/9 | 0/253 | 0/49 | 0/18 | 0/92 | 1/106 | 0/51 | 0/51 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/30 | 0/174 | 0/208 | 0/9 | 0/253 | 0/49 | 0/18 | 0/92 | 1/106 | 0/51 | 0/51 |
| DehydrationMetabolism and nutrition disorders | 0/30 | 0/174 | 0/208 | 0/9 | 0/253 | 0/49 | 0/18 | 0/92 | 1/106 | 0/51 | 0/51 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/30 | 0/174 | 0/208 | 0/9 | 0/253 | 0/49 | 0/18 | 0/92 | 1/106 | 0/51 | 0/51 |
| Viral infectionInfections and infestations | 0/30 | 0/174 | 0/208 | 0/9 | 0/253 | 0/49 | 0/18 | 0/92 | 1/106 | 0/51 | 0/51 |
| Event | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site pain (PAIN)General disorders | 24/30 | 132/174 | 107/208 | 4/9 | 142/253 | 18/49 | 16/18 | 67/92 | 52/106 | 37/51 | 23/51 |
| Headache (HEADACHE)Nervous system disorders | 11/30 | 76/174 | 54/208 | 1/9 | 76/253 | 8/49 | 11/18 | 33/92 | 19/106 | 20/51 | 9/51 |
| Fatigue (FATIGUE)General disorders | 17/30 | 99/174 | 73/208 | 1/9 | 87/253 | 12/49 | 10/18 | 44/92 | 31/106 | 30/51 | 17/51 |
| Chills (CHILLS)General disorders | 6/30 | 16/174 | 19/208 | 1/9 | 30/253 | 5/49 | 8/18 | 16/92 | 9/106 | 4/51 | 5/51 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 7/30 | 38/174 | 25/208 | 1/9 | 45/253 | 9/49 | 6/18 | 16/92 | 11/106 | 17/51 | 5/51 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 5/30 | 25/174 | 16/208 | 1/9 | 32/253 | 6/49 | 2/18 | 8/92 | 8/106 | 7/51 | 2/51 |
| Injection site swelling (SWELLING)General disorders | 5/30 | 13/174 | 12/208 | 1/9 | 30/253 | 5/49 | 0/18 | 12/92 | 12/106 | 5/51 | 2/51 |
| Pyrexia (FEVER)General disorders | 5/30 | 7/174 | 8/208 | 1/9 | 6/253 | 3/49 | 2/18 | 4/92 | 2/106 | 2/51 | 2/51 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 0/30 | 21/174 | 18/208 | 1/9 | 42/253 | 4/49 | 0/18 | 9/92 | 8/106 | 6/51 | 4/51 |
| Vomiting (VOMITING)Gastrointestinal disorders | 0/30 | 4/174 | 0/208 | 0/9 | 12/253 | 1/49 | 2/18 | 2/92 | 1/106 | 1/51 | 2/51 |
Baseline analysis population was evaluated on safety population which included all participants who received the study intervention.
| Age, Customized(Participants) | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age — 12-17 Years | 30 | 0 | 0 | 9 | 0 | 0 | 18 | 0 | 0 | 0 | 0 | 57 |
| Age — 18-64 Years | 0 | 174 | 63 | 0 | 253 | 27 | 0 | 92 | 45 | 51 | 18 | 723 |
| Age — 65-84 Years | 0 | 0 | 143 | 0 | 0 | 22 | 0 | 0 | 61 | 0 | 33 | 259 |
| Age — Greater than or equal to 85 Years | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Sex: Female, Male(Participants) | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 19 | 100 | 123 | 5 | 138 | 23 | 8 | 60 | 58 | 35 | 27 | 596 |
| Male | 11 | 74 | 85 | 4 | 115 | 26 | 10 | 32 | 48 | 16 | 24 | 445 |
| Ethnicity (NIH/OMB)(Participants) | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 35 | 34 | 3 | 136 | 19 | 1 | 20 | 29 | 6 | 9 | 298 |
| Not Hispanic or Latino | 24 | 138 | 173 | 6 | 117 | 30 | 17 | 72 | 76 | 44 | 42 | 739 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 4 |
| Race (NIH/OMB)(Participants) | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years | SSC - Cohort 2: 12-17 Years | SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | SSC - Cohort 1 and Cohort 2 Combined: >55 Years | SSC - Cohort 3: 18-55 Years | SSC - Cohort 3: >55 Years | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 4 |
| Asian | 1 | 11 | 10 | 0 | 4 | 2 | 0 | 6 | 6 | 4 | 6 | 50 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 |
| Black or African American | 3 | 23 | 27 | 7 | 87 | 16 | 2 | 20 | 16 | 6 | 7 | 214 |
| White | 26 | 135 | 164 | 2 | 162 | 30 | 15 | 60 | 76 | 39 | 37 | 746 |
| More than one race | 0 | 5 | 3 | 0 | 0 | 0 | 1 | 4 | 6 | 2 | 1 | 22 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2023 to primary completion in Mar 2025, 19 months.
Results were first posted in Apr 2026, 1 year 1 month after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 19 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine